INT210597

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 5.66
Pain Relevance 0.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (TNFSF11) intracellular (TNFSF11) cell-cell signaling (TNFRSF11A)
response to stress (TNFSF11) cytoplasm (TNFSF11) extracellular space (TNFSF11)
Anatomy Link Frequency
osteoclast 2
TNFSF11 (Homo sapiens)
TNFRSF11A (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 10 95.76 Very High Very High Very High
Osteoarthritis 66 89.04 High High
Inflammation 4 47.64 Quite Low
cva 33 41.08 Quite Low
headache 6 8.96 Low Low
Pain 3 6.52 Low Low
Potency 9 5.00 Very Low Very Low Very Low
Bioavailability 7 5.00 Very Low Very Low Very Low
antagonist 7 5.00 Very Low Very Low Very Low
withdrawal 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Metastasis 95 99.26 Very High Very High Very High
Disorders Of Creatine Metabolism 6 98.04 Very High Very High Very High
Renal Failure 3 96.72 Very High Very High Very High
Osteoporosis 301 96.56 Very High Very High Very High
Necrosis 6 93.96 High High
Cancer 73 93.60 High High
Apoptosis 12 93.20 High High
Prostate Cancer 17 93.16 High High
Alopecia 3 90.76 High High
Osteoarthritis 66 89.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
On the other hand, OPG is considered a decoy receptor that blocks the binding of RANKL to the RANK receptor, located on osteoclast precursors, thereby inhibiting the terminal stage of osteoclastic differentiation and suppressing its activation as well as inducing the apoptosis of mature osteoclasts.
Negative_regulation (blocks) of RANKL Binding (binding) of RANK in osteoclast associated with osteoporosis and apoptosis
1) Confidence 0.26 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 1.24 Pain Relevance 0.29
A prior study in our laboratory using a mouse intratibial injection model of metastasis demonstrated that blocking the RANK-RANKL interaction by RANK-Fc (a recombinant soluble fusion protein consisting of extracellular domain of RANK coupled with the Fc domain of human IgG) limits the formation of osteolytic bone lesions [44].
Negative_regulation (limits) of RANKL Binding (interaction) of RANK-Fc associated with metastasis
2) Confidence 0.22 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.51 Pain Relevance 0.04
Blockade of the RANK—RANK ligand (RANKL) pathway
Negative_regulation (Blockade) of RANKL Binding (ligand) of RANK
3) Confidence 0.06 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 1.10 Pain Relevance 0
Blockade of the RANK—RANK ligand (RANKL) pathway
Negative_regulation (Blockade) of RANKL Binding (ligand) of RANK
4) Confidence 0.06 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 1.10 Pain Relevance 0
This antibody, named denosumab, has been shown to specifically bind to RANKL with a very high affinity, preventing its interaction with the receptor RANK.
Negative_regulation (preventing) of RANKL Binding (interaction) of RANK
5) Confidence 0.05 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.72 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox